This website uses its own and third-party cookies. Some of these cookies are used to develop analytical statistics of visits to the webpage, others to manage advertising or even others are necessary for the correct management of the site. If you continue to browse or click in accept we consider you accept the conditions for their use. You can get more information, or learn how to change the settings in our cookies policy?
Versión Española Versión Mexicana Ibercampus English Version Version française Versione italiana

21/5/2019  
    Ibercampus  | Editorial Board | Who we are | Ideology | Contact | Advertising rates | Subscription | RSS RSS
Policies
Inclusion policies
R&D
Employment
Economics
Culture
Green strategies
Health
Society and consumer
Sports
Debates
Interviews
Education
Grants & internships
Training
Trends
Enterprises & CSR
 Enterprises & CSR
ACNUR
AEGON
AIR LIQUIDE
ALCATEL-LUCENT
ALLIANZ
ARCELORMITTAL
ASIFIN
ASSICURAZIONI GENERALI
AXA
BANCO SANTANDER
BASF
BAYER
BBVA
BNP PARIBAS
CARREFOUR
DAIMLER AG
DEUTSCHE BANK
DEUTSCHE BÖRSE
DEUTSCHE TELEKOM
E.ON
ENEL
ENI
FORTIS
FRANCE TÉLÉCOM
GROUPE DANONE
IBERDROLA
INDITEX
ING GROUP
INTESA SANPAOLO
L'ORÉAL
LVMH
MUNICH RE
NOKIA
PHILIPS
RENAULT
REPSOL YPF
RWE
SAINT GOBAIN
SANOFI-AVENTIS
SAP AG
SCHNEIDER ELECTRIC
SIEMENS AG
SOCIÉTÉ GÉNÉRALE
SUEZ
TELECOM ITALIA
TELEFÓNICA
TOTAL S.A.
UNICREDIT
UNILEVER
VINCI
VIVENDI
VOLKSWAGEN

HEALTH
New technology to identify the presence of cancer

Cambridge Institute investigates a blood tests to monitor tumors instead of biopsies


AstraZeneca Plc (AZN) is pursuing three research projects with the University of Cambridge and Cancer Research UK to try to identify changes in tumor cells and test combinations of its drugs to better treat some cancer patients. The projects include using blood tests to monitor tumors instead of biopsies, potential drugs for prostate cancer, and new approaches for pancreatic cáncer.
Redacción 10/7/2013 Send to a friend
Comparte esta noticia en TwitterFacebookTwitterdel.icio.usYahooRSS

The U.K.’s second-biggest drugmaker, AstraZeneca  will work with Cancer Research UK Cambridge Institute and the University of Cambridge Department of Oncology on a new technology that measures tumor DNA circulating in the blood and can identify the presence of cancer in plasma. The test can detect whether cancer is progressing and treatment is working. Doctors now use biopsies or imaging to monitor progression of the disease and whether the patient is responding to treatment.

The projects include using blood tests to monitor tumors instead of biopsies, potential drugs for prostate cancer, and new approaches for pancreatic cancer, which has a very poor prognosis and few treatments available, the company said on Tuesday.

The agreement supports Chief Executive Officer Pascal Soriot’s plan to use acquisitions, partnerships and the company’s own research to replace revenue lost to patent expirations. AstraZeneca can use the information to design medicines as the test can determine new genetic alterations to target, said Carl Barrett, vice president of translational science in AstraZeneca’s Oncology Innovative Medicines unit.

The company and Cancer Research UK Cambridge Institute will work with Addenbrooke’s Hospital and Cambridge University Hospitals to test AstraZeneca’s experimental cancer treatment olaparib in combination with another therapy called AZD2014 to treat advanced prostate cancer patients with a poor prognosis. Olaparib, which prevents cancer cells from repairing themselves, has been shown to benefit patients with the BRCA mutations. The combination therapy may help patients without the mutation respond to the treatment.


AstraZeneca will team up with the Babraham Institute in Cambridge and its Cancer Research UK and Cambridge University partners to develop new therapies for patients with pancreatic cancer. Patients diagnosed with this type of cancer often don’t have long to live and there are few treatments available, Barrett said. The program will test the company’s experimental treatment selumetinib in combination with other therapies in laboratory models, Barrett said.

Other issues Health
The electronic cigarette is not free from toxic elements
Are you really you when you´re hungry?
Are Breast Cancer Apps Reliable?
New studies show dark chocolate consumption reduces stress and inflammation
Wef
Can you really be obese yet healthy?
Simple urine test could help predict the risk of developing age-related disease and even death
Video games to improve mobility after a stroke
Why you feel hungrier after you lose weight
Second hand plastic toys could pose a risk to children´s health, study suggests

Subscribe free to our newsletter
Vanity Fea
My definition of narrative
José Ángel García Landa
We can all be leaders
VIDEOCOMMUTING A NEW ORGANIZATIONAL REALITY THAT POSITIVELY IMPACTS EMPLOYEES
Mar Souto Romero
Financial inclusion
Financial Education For All!
Carlos Trias
Brusselian Lights
European elections (I): which words are more used in the European political manifestos?
Raúl Muriel Carrasco
Humor and Political Communication
Comisión de Arbitraje, Quejas y Deontología (Spain) (3) You can´t be too careful
Felicísimo Valbuena
Want your own blog? Want to be read by universities?
Find out here
Books
The EU "An Obituary"
Startup Cities "Why Only a Few Cities Dominate the Global Startup Scene"
Blockchain Revolution "How the Technology Behind Bitcoin and Cryptocurrency Is Changing the World "
Doughnut Economics "Seven Ways to Think Like a 21st-Century Economist "
The People vs Tech "How the Internet Is Killing Democracy"
Will Big Business Destroy Our Planet?
Theses and dissertations
1 My definition of narrative
Legal Advise | Privacy Policy | Editorial Board | Who we are | Ideology | Contact | Advertising rates | RSS RSS